Promethazine Therapeutic Range
There is no established therapeutic plasma concentration range for promethazine in clinical practice. Promethazine dosing is guided by clinical indication and response rather than plasma drug levels, as therapeutic drug monitoring is not routinely performed or clinically validated for this medication.
Pharmacokinetic Parameters
The available evidence provides pharmacokinetic data rather than therapeutic ranges:
Plasma Half-Life: The plasma half-life of promethazine is 9-16 hours 1, 2. This relatively long half-life allows for dosing intervals of 4-8 hours depending on the indication.
Onset and Duration of Action:
- Clinical effects are evident within 5 minutes of intravenous administration 1, 2
- Duration of action is 4-6 hours 1, 2
Dosing Guidelines (Not Plasma Levels)
Since therapeutic ranges are not established, clinical practice relies on dose-based guidelines 3:
Standard Adult Dosing:
- Antiemetic use: 12.5-25 mg IV (infused slowly at ≤25 mg/min) 1, 2
- Total dose range: 25-50 mg as adjuvant to narcotics/benzodiazepines 2
- Breakthrough nausea/vomiting: 12.5-25 mg PO/IV every 4-6 hours 4
- Nausea in pregnancy: 12.5-25 mg every 4-8 hours PO, IM, or IV 5
Pharmacokinetic Variability
Research demonstrates high interindividual variability in promethazine absorption and bioavailability:
- Oral bioavailability is only 25% due to extensive first-pass hepatic metabolism 6
- Individual relative bioavailabilities range from 4% to 343% 7
- Peak plasma concentrations (Cmax) after 50 mg oral dose average 10-19 ng/mL, but this varies substantially 7, 8
This extreme variability explains why therapeutic drug monitoring is impractical—plasma levels do not reliably predict clinical response.
Clinical Implications
Dose titration based on clinical effect is the standard approach rather than targeting specific plasma concentrations. The FDA-approved labeling 3 emphasizes adjusting "dosage to the smallest amount adequate to relieve symptoms" after treatment initiation.
Important Safety Considerations:
- Promethazine requires slow IV infusion (≤25 mg/min) to minimize hypotension risk 1, 2
- Contraindicated in children under 2 years due to respiratory depression risk 3
- Serious adverse effects include tissue necrosis with extravasation, respiratory depression, and extrapyramidal effects 2
The absence of established therapeutic ranges reflects promethazine's use as a symptomatic treatment where clinical response—not plasma concentration—guides therapy.